Prostate cancer screening centers on a simple blood test that measures a protein called PSA, or prostate-specific antigen. The test itself takes minutes, but the decisions around it (when to start, how often to repeat it, and what to do with the results) involve more nuance than most people expect. Here’s what the full screening process looks like, from the first conversation with your doctor to the follow-up steps if something comes back abnormal.
The PSA Blood Test
PSA is a protein produced by both normal and cancerous cells in the prostate gland. A standard blood draw measures how much of this protein is circulating in your bloodstream. Higher levels can signal cancer, but they can also result from completely benign conditions like an enlarged prostate or a prostate infection. That overlap is one reason screening requires careful interpretation rather than a simple pass/fail.
A PSA level of 4.0 ng/mL has traditionally been used as a threshold for further investigation, though many doctors now consider trends over time and individual risk factors rather than relying on a single cutoff. Before your blood draw, you’ll typically be told to avoid sexual activity and vigorous exercise for about two days, since both can temporarily raise PSA levels. If you have an active urinary tract infection or prostatitis, it’s best to wait until that clears before testing.
The Digital Rectal Exam
During a digital rectal exam (DRE), a doctor inserts a gloved, lubricated finger into the rectum to feel the surface of the prostate for hard spots, lumps, or unusual texture. The exam takes about 10 to 15 seconds. It’s uncomfortable but not painful for most people.
The U.S. Preventive Services Task Force no longer recommends the DRE as a standalone screening tool because it misses many cancers and has limited evidence of improving outcomes on its own. However, some doctors still use it alongside the PSA test, particularly to catch cancers that don’t produce elevated PSA levels. It can also flag signs of infection or significant enlargement that might explain a borderline PSA result.
When to Start Screening
The right age to begin depends on your personal risk. The American Cancer Society recommends having the screening conversation at these ages:
- Age 50 for men at average risk who are expected to live at least 10 more years
- Age 45 for men at high risk, including Black men and men with a father or brother diagnosed with prostate cancer before age 65
- Age 40 for men at the highest risk, specifically those with more than one first-degree relative diagnosed at an early age
These aren’t ages to automatically start testing. They’re ages to have an informed discussion about whether the benefits outweigh the risks for you personally. The USPSTF does not recommend screening unless you’ve been informed of both the potential benefits and harms and express a preference to be tested.
Why Race and Family History Matter
Black men face roughly 75% higher risk of developing prostate cancer compared to white men, and the disease is more than twice as deadly in this group. Research from the largest and most diverse genetic study of prostate cancer found that men of African ancestry inherit about double the genetic risk on average compared to men of European ancestry. Men of Asian ancestry, by contrast, inherit about three-quarters the risk of white men. These differences are partly genetic: scientists have identified 269 genetic variations linked to prostate cancer risk so far, with 86 discovered in the most recent large-scale study.
Family history compounds this. Having a father or brother with prostate cancer significantly raises your own odds, especially if they were diagnosed young. If both of these risk factors apply to you (Black and a close relative with prostate cancer), starting the conversation at 40 rather than 50 is reasonable.
How Often to Repeat Screening
Annual screening was once the default, but evidence now favors longer intervals for most men. Screening every two to four years appears to offer nearly the same reduction in cancer deaths as annual testing while substantially reducing the chance of a false alarm or unnecessary biopsy. In major European clinical trials, no study site screened men more frequently than every two years, and many screened every four years.
Your doctor may suggest shorter intervals if your PSA level is on the higher end of normal, or longer intervals if your level is very low. A man in his early 50s with a PSA well below 1.0 ng/mL, for example, has very low near-term risk and may not need another test for several years.
What Happens After an Abnormal Result
An elevated PSA or a suspicious finding on a rectal exam doesn’t mean you have cancer. It means more investigation is needed. The next step is usually one of two paths: additional blood tests to refine your risk estimate, or imaging followed by a biopsy.
Secondary Blood and Urine Tests
Before jumping to a biopsy, your doctor may order a follow-up test to better estimate how likely it is that you actually have aggressive cancer. The 4Kscore test is a blood test that calculates your risk of harboring aggressive prostate cancer based on four different proteins. The Prostate Health Index (PHI) combines three related blood measurements into a single score that predicts the likelihood of finding cancer on a biopsy. Both tests exist specifically to help men with borderline PSA results avoid an unnecessary biopsy.
MRI and Biopsy
If your risk still appears elevated after secondary testing, or if your initial results were clearly abnormal, the next step is typically a multiparametric MRI (mpMRI). This specialized scan is highly sensitive and can pinpoint suspicious areas within the prostate that deserve a closer look. However, an MRI alone cannot rule out cancer.
A prostate biopsy is usually still necessary for a definitive answer. The most precise approach is a fusion-guided biopsy, which overlays MRI images onto a real-time ultrasound during the procedure. This lets the doctor target the exact suspicious spots identified on the MRI rather than sampling the prostate randomly. If the biopsy comes back negative but your risk factors remain concerning, your doctor may recommend repeating the biopsy in a few months.
The Overdiagnosis Trade-Off
The most important thing to understand about prostate cancer screening is that it catches cancers that would never have caused symptoms or shortened your life. This is called overdiagnosis, and it’s not rare. Modeling studies estimate that 20 to 40% of screen-detected prostate cancers are overdiagnosed, meaning the man would have lived out his life without ever knowing the cancer existed had he not been screened.
Overdiagnosis matters because treatment carries real consequences. Surgery and radiation for prostate cancer can cause lasting urinary incontinence and erectile dysfunction. When the cancer detected was one that never would have progressed, those side effects represent harm without benefit. This is the core reason screening guidelines emphasize shared decision-making rather than blanket recommendations. For a 55-year-old Black man with a family history, the math tilts strongly toward screening. For a 70-year-old with no risk factors and other significant health conditions, it may tilt the other way.
Screening every two to four years instead of annually helps reduce overdiagnosis. Using secondary tests like the 4Kscore or PHI before proceeding to biopsy helps further. And if a biopsy does find low-grade cancer, active surveillance (regular monitoring without immediate treatment) is now a well-established option that avoids the side effects of treatment while keeping close watch for any changes.